Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma
Hodgkin lymphoma (HL) is a lymphoid-type hematologic disease that is derived from B cells. The incidence of this lymphoid malignancy is around 2–3/100,000/year in the western world. Long-term remission rates are linked to a risk-adapted approach, which allows remission rates higher than 80%. The fir...
Gespeichert in:
Veröffentlicht in: | Cancers 2021-07, Vol.13 (15), p.3745 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 15 |
container_start_page | 3745 |
container_title | Cancers |
container_volume | 13 |
creator | Vellemans, Hélène André, Marc P. E. |
description | Hodgkin lymphoma (HL) is a lymphoid-type hematologic disease that is derived from B cells. The incidence of this lymphoid malignancy is around 2–3/100,000/year in the western world. Long-term remission rates are linked to a risk-adapted approach, which allows remission rates higher than 80%. The first-line treatment for advanced stage classical HL (cHL) widely used today is doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) chemotherapy. Randomized studies comparing these two regimens and a recently performed meta-analysis have demonstrated consistently better disease control with BEACOPPesc. However, this treatment is not the standard of care, as there is an excess of acute hematological toxicities and therapy-related myeloid neoplasms. Moreover, there is a recurrent controversy concerning the impact on overall survival with this regimen. More recently, new drugs such as brentuximab vedotin and checkpoint inhibitors have become available and have been evaluated in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the first-line treatment of patients with advanced cHL with the objective of tumor control improvement. There are still major debates with respect to first-line treatment of advanced cHL. The use of positron emission tomography-adapted strategies has allowed a reduction in the toxicity of chemotherapy regimens. Incorporation of new drugs into the treatment algorithms requires confirmation. |
doi_str_mv | 10.3390/cancers13153745 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8345175</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2559433782</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-f529c60040e8f0499b03574820074193edc28ed5a2fd7e3cac128db1bbc850573</originalsourceid><addsrcrecordid>eNpdkU1LAzEQhoMoWqpnrwEvXqpJJtkkF0GKX1ARv84hm822q91NTbaV_ntTFVHnMsPMwzvvMAgdUnICoMmps53zMVGgAiQXW2jAiGSjotB8-1e9hw5SeiE5AKgs5C7aAw5CF7wYoPsHv2r8Ow41fore9q3veny36JvQJVyHiPuZx7e2s1P_OcrcebXaLK7wY5-7-DpU09emw5N1u5iF1u6jndrOkz_4zkP0fHnxNL4eTe6ubsbnk5EDrfpRLZh2BSGceFUTrnVJQEiuGCGSUw2-ckz5SlhWV9KDs44yVZW0LJ0SREgYorMv3cWybDOd3UU7N4vYtDauTbCN-TvpmpmZhpVRwAWVIgscfwvE8Lb0qTdtk5yfz23nwzIZJoTmAFKxjB79Q1_CMnb5vA2lJJOcFJk6_aJcDClFX_-YocRsPmb-fQw-ANw0iLE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2558727406</pqid></control><display><type>article</type><title>Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Vellemans, Hélène ; André, Marc P. E.</creator><creatorcontrib>Vellemans, Hélène ; André, Marc P. E.</creatorcontrib><description>Hodgkin lymphoma (HL) is a lymphoid-type hematologic disease that is derived from B cells. The incidence of this lymphoid malignancy is around 2–3/100,000/year in the western world. Long-term remission rates are linked to a risk-adapted approach, which allows remission rates higher than 80%. The first-line treatment for advanced stage classical HL (cHL) widely used today is doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) chemotherapy. Randomized studies comparing these two regimens and a recently performed meta-analysis have demonstrated consistently better disease control with BEACOPPesc. However, this treatment is not the standard of care, as there is an excess of acute hematological toxicities and therapy-related myeloid neoplasms. Moreover, there is a recurrent controversy concerning the impact on overall survival with this regimen. More recently, new drugs such as brentuximab vedotin and checkpoint inhibitors have become available and have been evaluated in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the first-line treatment of patients with advanced cHL with the objective of tumor control improvement. There are still major debates with respect to first-line treatment of advanced cHL. The use of positron emission tomography-adapted strategies has allowed a reduction in the toxicity of chemotherapy regimens. Incorporation of new drugs into the treatment algorithms requires confirmation.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13153745</identifier><identifier>PMID: 34359646</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Bleomycin ; Cardiovascular diseases ; Chemotherapy ; Cyclophosphamide ; Dacarbazine ; Disease control ; Doxorubicin ; Etoposide ; Fertility ; Hematological diseases ; Hematology ; Hodgkin's lymphoma ; Immune checkpoint ; Lymphocytes ; Lymphocytes B ; Lymphoma ; Malignancy ; Medical prognosis ; Neutropenia ; Patients ; Positron emission tomography ; Prednisone ; Procarbazine ; Radiation therapy ; Remission ; Remission (Medicine) ; Review ; Toxicity ; Vinblastine ; Vincristine ; Women ; Young adults</subject><ispartof>Cancers, 2021-07, Vol.13 (15), p.3745</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-f529c60040e8f0499b03574820074193edc28ed5a2fd7e3cac128db1bbc850573</citedby><cites>FETCH-LOGICAL-c398t-f529c60040e8f0499b03574820074193edc28ed5a2fd7e3cac128db1bbc850573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345175/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345175/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Vellemans, Hélène</creatorcontrib><creatorcontrib>André, Marc P. E.</creatorcontrib><title>Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma</title><title>Cancers</title><description>Hodgkin lymphoma (HL) is a lymphoid-type hematologic disease that is derived from B cells. The incidence of this lymphoid malignancy is around 2–3/100,000/year in the western world. Long-term remission rates are linked to a risk-adapted approach, which allows remission rates higher than 80%. The first-line treatment for advanced stage classical HL (cHL) widely used today is doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) chemotherapy. Randomized studies comparing these two regimens and a recently performed meta-analysis have demonstrated consistently better disease control with BEACOPPesc. However, this treatment is not the standard of care, as there is an excess of acute hematological toxicities and therapy-related myeloid neoplasms. Moreover, there is a recurrent controversy concerning the impact on overall survival with this regimen. More recently, new drugs such as brentuximab vedotin and checkpoint inhibitors have become available and have been evaluated in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the first-line treatment of patients with advanced cHL with the objective of tumor control improvement. There are still major debates with respect to first-line treatment of advanced cHL. The use of positron emission tomography-adapted strategies has allowed a reduction in the toxicity of chemotherapy regimens. Incorporation of new drugs into the treatment algorithms requires confirmation.</description><subject>Bleomycin</subject><subject>Cardiovascular diseases</subject><subject>Chemotherapy</subject><subject>Cyclophosphamide</subject><subject>Dacarbazine</subject><subject>Disease control</subject><subject>Doxorubicin</subject><subject>Etoposide</subject><subject>Fertility</subject><subject>Hematological diseases</subject><subject>Hematology</subject><subject>Hodgkin's lymphoma</subject><subject>Immune checkpoint</subject><subject>Lymphocytes</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Malignancy</subject><subject>Medical prognosis</subject><subject>Neutropenia</subject><subject>Patients</subject><subject>Positron emission tomography</subject><subject>Prednisone</subject><subject>Procarbazine</subject><subject>Radiation therapy</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Review</subject><subject>Toxicity</subject><subject>Vinblastine</subject><subject>Vincristine</subject><subject>Women</subject><subject>Young adults</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU1LAzEQhoMoWqpnrwEvXqpJJtkkF0GKX1ARv84hm822q91NTbaV_ntTFVHnMsPMwzvvMAgdUnICoMmps53zMVGgAiQXW2jAiGSjotB8-1e9hw5SeiE5AKgs5C7aAw5CF7wYoPsHv2r8Ow41fore9q3veny36JvQJVyHiPuZx7e2s1P_OcrcebXaLK7wY5-7-DpU09emw5N1u5iF1u6jndrOkz_4zkP0fHnxNL4eTe6ubsbnk5EDrfpRLZh2BSGceFUTrnVJQEiuGCGSUw2-ckz5SlhWV9KDs44yVZW0LJ0SREgYorMv3cWybDOd3UU7N4vYtDauTbCN-TvpmpmZhpVRwAWVIgscfwvE8Lb0qTdtk5yfz23nwzIZJoTmAFKxjB79Q1_CMnb5vA2lJJOcFJk6_aJcDClFX_-YocRsPmb-fQw-ANw0iLE</recordid><startdate>20210726</startdate><enddate>20210726</enddate><creator>Vellemans, Hélène</creator><creator>André, Marc P. E.</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210726</creationdate><title>Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma</title><author>Vellemans, Hélène ; André, Marc P. E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-f529c60040e8f0499b03574820074193edc28ed5a2fd7e3cac128db1bbc850573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bleomycin</topic><topic>Cardiovascular diseases</topic><topic>Chemotherapy</topic><topic>Cyclophosphamide</topic><topic>Dacarbazine</topic><topic>Disease control</topic><topic>Doxorubicin</topic><topic>Etoposide</topic><topic>Fertility</topic><topic>Hematological diseases</topic><topic>Hematology</topic><topic>Hodgkin's lymphoma</topic><topic>Immune checkpoint</topic><topic>Lymphocytes</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Malignancy</topic><topic>Medical prognosis</topic><topic>Neutropenia</topic><topic>Patients</topic><topic>Positron emission tomography</topic><topic>Prednisone</topic><topic>Procarbazine</topic><topic>Radiation therapy</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Review</topic><topic>Toxicity</topic><topic>Vinblastine</topic><topic>Vincristine</topic><topic>Women</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vellemans, Hélène</creatorcontrib><creatorcontrib>André, Marc P. E.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vellemans, Hélène</au><au>André, Marc P. E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma</atitle><jtitle>Cancers</jtitle><date>2021-07-26</date><risdate>2021</risdate><volume>13</volume><issue>15</issue><spage>3745</spage><pages>3745-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Hodgkin lymphoma (HL) is a lymphoid-type hematologic disease that is derived from B cells. The incidence of this lymphoid malignancy is around 2–3/100,000/year in the western world. Long-term remission rates are linked to a risk-adapted approach, which allows remission rates higher than 80%. The first-line treatment for advanced stage classical HL (cHL) widely used today is doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) chemotherapy. Randomized studies comparing these two regimens and a recently performed meta-analysis have demonstrated consistently better disease control with BEACOPPesc. However, this treatment is not the standard of care, as there is an excess of acute hematological toxicities and therapy-related myeloid neoplasms. Moreover, there is a recurrent controversy concerning the impact on overall survival with this regimen. More recently, new drugs such as brentuximab vedotin and checkpoint inhibitors have become available and have been evaluated in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the first-line treatment of patients with advanced cHL with the objective of tumor control improvement. There are still major debates with respect to first-line treatment of advanced cHL. The use of positron emission tomography-adapted strategies has allowed a reduction in the toxicity of chemotherapy regimens. Incorporation of new drugs into the treatment algorithms requires confirmation.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34359646</pmid><doi>10.3390/cancers13153745</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2072-6694 |
ispartof | Cancers, 2021-07, Vol.13 (15), p.3745 |
issn | 2072-6694 2072-6694 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8345175 |
source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
subjects | Bleomycin Cardiovascular diseases Chemotherapy Cyclophosphamide Dacarbazine Disease control Doxorubicin Etoposide Fertility Hematological diseases Hematology Hodgkin's lymphoma Immune checkpoint Lymphocytes Lymphocytes B Lymphoma Malignancy Medical prognosis Neutropenia Patients Positron emission tomography Prednisone Procarbazine Radiation therapy Remission Remission (Medicine) Review Toxicity Vinblastine Vincristine Women Young adults |
title | Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T00%3A34%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20of%20Treatment%20Options%20for%20the%20Management%20of%20Advanced%20Stage%20Hodgkin%20Lymphoma&rft.jtitle=Cancers&rft.au=Vellemans,%20H%C3%A9l%C3%A8ne&rft.date=2021-07-26&rft.volume=13&rft.issue=15&rft.spage=3745&rft.pages=3745-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13153745&rft_dat=%3Cproquest_pubme%3E2559433782%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2558727406&rft_id=info:pmid/34359646&rfr_iscdi=true |